Circio fundamentale forhold (CRNA, tidl. TRVX)

[Morgo26]

Every kr counts!

[Silvertailfox]

Jeg prøvde meg på en liten overtegning men usikker om jeg får.

Men de er Top 3 nyttårsrakett enda

Dette er samlede Oslo Børs «nyttårsraketter»:

1. Siem Offshore
2. Norwegian Air Shuttle
3. Targovax

[Dr.Stonks]

@Silvertailfox

Jeg prøvde meg på en liten overtenning men usikker om jeg får.

Har hatt overtenning på targo noen år selv, fikk heldigvis overtegna i emisjon for å dempe tenninga litt😉

[Silvertailfox]

Magisk med auto korrekt

[TekBot]

Targovax ASA: Primary insiders share purchase

Erik Digman Wiklund, Chief Executive Officer of Targovax and primary insider,
has on 16 December 2021 purchased 100,000 shares in Targovax ASA (“the Company”)
at an average share price of NOK 2.01 per share. Following this transaction,
…

Vis børsmeldingen

Erik Digman Wiklund and his close associates (Digman AS) holds 100,000 shares
and 1,000,000 share options in the Company.

Please see the attached notification of trade for further information.

Notification by Primary Insider_Wiklund
purchase.pdf (https://mb.cision.com/Public/17093/3473496/9dc04ffd01779094.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients. Targovax’s pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company’s product candidates are designed to harness the
patient’s own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.

Kilde

[Silvertailfox]

Er det lov til og å få enda mer overtenning nå…

[TekBot]

Targovax ASA: Primary insider share purchase

Lone Ottesen, Chief Development Officer at Targovax and primary insider, has on
16 December 2021 purchased 47,000 shares in Targovax ASA (“the Company”) at an
average share price of NOK 2.26 per share.
…

Vis børsmeldingen

Following this transaction, Lone Ottesen and her close associates holds 47,000
shares and 350,000 share options in the Company.

Please see the attached notification of trade for further information.

Notification by Primary Insider_Ottesen
purchase.pdf (https://mb.cision.com/Public/17093/3473741/b3f6c28f4a2bd848.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients. Targovax’s pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company’s product candidates are designed to harness the
patient’s own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.

Kilde

[morris]

De (insiderne) vet nok hva som kommer uansett om det vil ta tid!
Har selv tatt masse T-retter, sitter og med aksjer.
Dette blir bra hvis en er tålmodig

[Silvertailfox]

[TekBot]

Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma

The median overall survival (mOS) was 25.0 months in the first-line group of
patients treated with ONCOS-102 plus chemotherapy, compared with 13.5 months mOS
for the chemotherapy-only control group
…

Vis børsmeldingen

Oslo, Norway, 20 December 2021 - Targovax ASA (OSE: TRVX), a clinical-stage
immuno-oncology company developing immune activators to target hard-to-treat
solid tumors, today announces mOS of 25.0 months for treatment with ONCOS-102 in
combination with Standard of Care (SoC) chemotherapy in malignant pleural
mesothelioma (MPM) in the subgroup of patients receiving therapy in the first
-line setting.

The study is an open-label, exploratory phase 1/2 trial adding ONCOS-102 to SoC
chemotherapy (pemetrexed/cisplatin) in first and later line MPM to assess
safety, immune activation and clinical efficacy compared with SoC alone. A total
of 31 patients were enrolled in the trial, with 20 patients in the treatment
group receiving ONCOS-102 plus SoC chemotherapy, and 11 patients in the control
group receiving SoC only. The 30-month follow-up has now been completed.

At the 30-month follow-up, mOS was 25.0 months for the subgroup of randomized,
first-line ONCOS-102-treated patients (n=8). This is a clear improvement over
the mOS of 13.5 months observed in the first-line SoC-only control group (n=6).
Previous phase 3 clinical trials in MPM have reported mOS in the range of 12-16
months for patients receiving the same SoC chemotherapy treatment in the first
-line setting[1]. The combination of Opdivo/Yervoy double checkpoint inhibition
was recently approved as a first-line treatment option for MPM based on a phase
3 trial showing 18.1 months mOS[2].

Objective response rate (ORR), progression free survival (PFS) and mOS have been
previously reported, and remain unchanged. The 30-month follow-up analysis
completes the mOS data set for all subgroups in the trial.

Immune activation was assessed in tumor biopsies pre- and post-ONCOS-102
treatment (Day 0 and Day 36). The tumor tissue analyses revealed powerful and
consistent ONCOS-102-induced remodeling of the tumor microenvironment with
increased T-cell infiltration and a shift towards pro-inflammatory immune cells,
far beyond what was observed for the SoC-only control group. This immune
activation is associated with tumor responses and is most pronounced in patients
with better survival outcomes, indicating that the immune activating capacity of
ONCOS-102 is driving the clinical benefit for patients.

Dr. Magnus Jäderberg, Chief Medical Officer of Targovax, commented: “This
excellent survival outcome suggests a great promise for ONCOS-102 to benefit
mesothelioma patients. The results complement the class-leading ORR and immune
activation ONCOS-102 has demonstrated in anti-PD1 resistant melanoma by showing
that ONCOS-102 can be used in combination with both chemotherapy and anti-PD1
checkpoint inhibition. Importantly, we have confirmed that ONCOS-102 is active
and effective in highly different types of solid tumors in both early and late
lines of therapy. Based on the encouraging patient outcomes and deep mechanistic
analysis from the phase 1/2 program, we are currently designing and preparing
for the next phase in ONCOS-102 clinical development.”

1 Vogelzang 2003, Ceresoli 2006, Zalcman 2015, Tsao 2019, Scagliotti 2019, Baas
2020 SITC 2020 poster

2 Baas et al. The Lancet, 2021

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients. Targovax’s pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company’s product candidates are designed to harness the
patient’s own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.

Kilde

[TekBot]

Targovax ASA - Registration of share capital increase pertaining to the Rights Issue

22 December 2021: Reference is made to Targovax ASA’s (the “Company”) stock
exchange announcement published on 15 December 2021, regarding the final result
of the rights issue of 101,744,186 new shares in the Company (the "Offer
…

Vis børsmeldingen

Shares") at a subscription price of NOK 1.72 per Offer Share (the “Rights
Issue”).

The share capital increase pertaining to the Rights Issue has now been
registered in the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret). The Company’s new share capital is NOK 18,832,659.10
divided into 188,326,591 shares, each with a nominal value of NOK 0,10.

Delivery of the Offer Shares in the Norwegian Central Securities Depository (the
VPS) to the subscribers having been allocated Offer Shares in the Rights Issue
is expected to take place tomorrow, on 23 December 2021, however trading in the
Offer Shares on the Oslo Stock Exchange with ordinary T+2 settlement may
accordingly commence now.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients. Targovax’s pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company’s product candidates are designed to harness the
patient’s own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.

Kilde

[TekBot]

NOTICE OF CHANGED SHAREHOLDING

NOTICE OF CHANGED SHAREHOLDING
(mutually from Avanza Bank Holding AB (publ) and Försäkringsaktiebolaget Avanza Pension)

…

Vis børsmeldingen

Försäkringsaktiebolaget Avanza Pension, organization number 516401-6775, (”Avanza Pension”) has on December 22nd 2021 increased its shareholding in Targovax ASA. Avanza Pension has on December 22nd 2021 been allocated 18 212 707 new shares in the Rights Issue in Targovax ASA (ISIN: NO0010689326) at the price of 1,72 NOK per share.

After the rights issue, the shareholding in Targovax ASA has increased to 18 275 939 shares which corresponds to 9,70 % of the total amount of shares and voting rights in Targovax ASA.

Avanza Pension is fully owned by the mother company Avanza Bank Holding AB (publ), organization number 556274-8458. The address to Avanza Bank Holding AB (publ) is Box 1399, 111 93 Stockholm, Sweden. The address to Avanza Pension is Box 13129, 103 03 Stockholm, Sweden.

Kilde

[solskimm]

Legger det ut her også, så en kan ha et forhold mellom aksjekursen og hva selskapet faktisk prises til:

Targovax - Småprat 2 (TRVX) 2

Her ser vi utviklingen i Targovax hvor det fundamentale aldri har vært priset lavere enn i disse tider. Ved kurs 1,72 (emi) vil verdien være 133,3mill for: ONCOS 102 plattform med 2x Fast Track Designations og best in class (Mesothelioma og refractory melanoma) TG Next gen virus preklinisk CRNA preklinisk Pågående studie i colorectal (samarbeid uten kostnad) Potensiell utlisensieringsavtale for Kina [image] Forbehold: Q4 datapunkt er satt med cashburn som Q3 21, tatt med forskningsmidler (…

[TekBot]

Targovax ASA issues options to employees

On the basis of the approval by the Annual General Meeting on 17 March 2021 to
authorize the Board of Targovax ASA to issue new shares to employees under the
Company long-term incentive program, the Board has resolved to issue new options
…

Vis børsmeldingen

to employees of the Company. A total of 585,000 options for shares of the
Company were distributed amongst members of the executive management and a total
of 585,000 options for shares of the Company were distributed amongst other
employees.

Each option, when exercised, will give the right to acquire one share in the
Company. The options are granted without consideration. Pursuant to the vesting
schedule, 25% of the options will vest 12 months after the day of grant (as long
as the option holder is still employed). Thereafter, 1/36 of the remaining
options will vest each month as long as the option holder is still employed,
with the first 1/36 vesting 13 months after the day of grant. The exercise price
of the options is NOK 2.18. The exercise price is equal to the volume weighted
average trading price of the shares of the Company on Oslo Børs on the date of
the grant. Options that have not been exercised will lapse 7 years after the
date of grant.

Primary insiders in Targovax ASA have received the following options grants,
according to the terms described above:

Chief Executive Officer Erik Digman Wiklund has been granted 200,000 share
options. Following the grant, he holds 100,000 shares and 1,200,000 options in
the Company.

Chief Development Officer Lone Ottesen has been granted 140,000 share options.
Following the grant, she holds 47,000 shares and 490,000 options in the Company.

VP Regulatory Affairs Ingunn Munch Lindvig has been granted 125,000 share
options. Following the grant, she holds 10,000 shares and 392,000 options in the
Company.

Head of Manufacturing Ola Melin has been granted 75,000 share options. Following
the grant, he holds 50,000 shares and 325,000 options in the Company.

Chief Scientific Officer Victor Levitsky has been granted 45,000 share options.
Following the grant, he holds 10,000 shares and 545,000 options in the Company.

PDMR notifications
23.12.21.pdf (https://mb.cision.com/Public/17093/3478198/9ed9f9d8375a4dc8.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients. Targovax’s pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company’s product candidates are designed to harness the
patient’s own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.

Kilde

[TheObserver]

Skulle jeg valgt meg en jobb med frynsegoder i norsk biotek hadde jeg gått for en stilling i Targovax fremfor de 40 rabattkupongene de får som ansatt i Nanovector.

Skjønner godt at det passet med en fortrinnsrettet emisjon på 1,72 NOK når årets opsjoner ennå ikke var settlet!

God Jul

[T.S]

God jul!

[TekBot]

Notification of changed shareholding

NOTICE OF CHANGED SHAREHOLDING
(mutually from Avanza Bank Holding AB (publ) and Försäkringsaktiebolaget Avanza Pension)

…

Vis børsmeldingen

Försäkringsaktiebolaget Avanza Pension, organization number 516401-6775, (”Avanza Pension”) has as end of trade date on December 28 2021 decreased its shareholding in Targovax ASA.

The shareholding in Targovax ASA (ISIN: NO0010689326) has decreased to 18 491 599 shares as of end of trade date on December 28 2021 which corresponds to 9,82 % of the total amount of shares and voting rights in

Avanza Pension is fully owned by the mother company Avanza Bank Holding AB (publ), organization number 556274-8458. The address to Avanza Bank Holding AB (publ) is Box 1399, 111 93 Stockholm, Sweden. The address to Avanza Pension is Box 13129, 103 03 Stockholm, Sweden.

It is underlying insurance clients to Avanza Pension who have sold the shares.

Kilde

[skjerm]

Er Avanza Pension ikke som Nordnet Livsforsikring AS og består av mange store og småsparere. Når man handler på Zerokonto blir registrert i Nordnet Livsforsikring AS.

Hvis ikke enten Avanza Pension som største aksjonær skal opphøre seg som klovn (stadig ut og inn) eller bruke sin makt til å stoppe shortere. Guevoura Fund Limited ble tvunget til å dekke sin short med tap.

[SebM]

De kan også ha dekket gjennom emisjonen, og gikk i så fall godt i pluss. Shorten var bare en måte å selge før de fikk aksjene.

[Krieghoff]

Fasiten står i den siste linjen i dagens børsmelding